LSN

[2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol

Find entries where: LSN

is present as a standalone ligand in 8 entries

Find related ligands:

Chemical Component Summary
Name	[2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
Synonyms	Losartan
Identifiers	[2-butyl-5-chloranyl-3-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
Formula	C₂₂ H₂₃ Cl N₆ O
Molecular Weight	422.911
Type	NON-POLYMER
Isomeric SMILES	CCCCc1nc(c(n1Cc2ccc(cc2)c3ccccc3c4n[nH]nn4)CO)Cl
InChI	InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
InChIKey	PSIFNNKUMBGKDQ-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	53
Chiral Atom Count	0
Bond Count	56
Aromatic Bond Count	22

Drug Info: DrugBank

DrugBank ID	DB00678
Name	Losartan
Groups	approved
Description	Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Synonyms	Losartan potassium 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole Losartan (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
Brand Names	Losartan potassium Auro-losartan HCT Jamp-losartan Hctz Losartan LOSARTAN POTASSIUM and HYDROCHLOROTHIAZIDE Auro-losartan Dom-losartan Losartan Pot/hctz PHL-losartan Priva-losartan Losartan potassium and hydrochlorothiazide Losortan Potassium Mint-losartan Septa-losartan Hctz Mint-losartan/hctz Act Losartan Act Losartan/hct Losartan Potassium and Hydrochlorothiazide Losartan/hct Mar-losartan LOSARTAN POTASSIUM 100 mg Van-losartan-hctz Losartan HCT Losartan potassium Tablets, 50 mg Mylan-losartan Losartan Potatssium Van-losartan Ipg-losartan Losartan Potassium HCTZ Losartan-hctz Sandoz Losartan HCT PMS-losartan LOSARTAN POTASSIUM 50 mg Taro-losartan Teva-losartan Losartan potassium Tablets, 25 mg Ag-losartan Hctz Ag-losartan Teva-losartan/hctz Losartan potassium Tablets, 100 mg Mint-losartan/hctz DS Mylan-losartan Hctz Apo-losartan LOSARTAN POTASSIUM 25 mg Losartan potassium and Hydrochlorothiazide Cozaar Apo-losartan/hctz Sandoz Losartan HCT DS Losartan Potassium Ratio-losartan Hctz Sandoz Losartan Septa-losartan Losartan/hctz Hyzaar DS Hyzaar PMS-losartan-hctz Jamp-losartan Bio-losartan Losatan Potassium
Indication	Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426,L45663]
Categories	Agents Acting on the Renin-Angiotensin System Agents causing angioedema Agents causing hyperkalemia Angiotensin 2 Receptor Blocker Angiotensin II receptor antagonists Angiotensin II receptor blockers (ARBs) and calcium channel blockers Angiotensin II receptor blockers (ARBs) and diuretics Angiotensin II receptor blockers (ARBs), plain Angiotensin II Type 1 Receptor Blockers Angiotensin II Type 2 Receptor Blockers Angiotensin Receptor Antagonists Antiarrhythmic agents Antihypertensive Agents Antihypertensive Agents Indicated for Hypertension Benzene Derivatives Biphenyl Compounds BSEP/ABCB11 Substrates Cardiovascular Agents Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2C19 inhibitors (strength unknown) Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Drugs causing inadvertant photosensitivity Hypotensive Agents Imidazoles OAT1/SLC22A6 inhibitors P-glycoprotein inhibitors P-glycoprotein substrates Photosensitizing Agents Potential QTc-Prolonging Agents QTc Prolonging Agents Tetrazoles UGT1A1 Substrates UGT1A3 substrates UGT2B17 substrates UGT2B7 substrates
ATC-Code	C09CA01 C09DA01 C09DB06
CAS number	114798-26-4

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Type-1 angiotensin II receptor	MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVV...	unknown	antagonist
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate,inhibitor
Cytochrome P450 2C19	MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...	unknown	inhibitor
UDP-glucuronosyltransferase 1-1	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...	unknown	substrate
UDP-glucuronosyltransferase 1-3	MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRE...	unknown	substrate
UDP-glucuronosyltransferase 1-10	MARAGWTSPVPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMQSVVEKLIL...	unknown	substrate
UDP-glucuronosyltransferase 2B7	MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRG...	unknown	substrate
UDP-glucuronosyltransferase 2B17	MSLKWMSVFLLMQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRG...	unknown	substrate
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	inhibitor
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	substrate
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate,inhibitor
Solute carrier family 22 member 6	MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR...	unknown	inhibitor
Solute carrier family 22 member 12	MAFSELLDLVGGLGRFQVLQTMALMVSIMWLCTQSMLENFSAAVPSHRCW...	unknown	inhibitor
Solute carrier family 2, facilitated glucose transporter member 9	MARKQNRNSKELGLVPLTDDTSHAGPPGPGRALLECDHLRSGVPGGRRRK...	unknown	inhibitor
Bile salt export pump	MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQL...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682